Vir Biotechnology Beheer

Beheer criteriumcontroles 1/4

De CEO Vir Biotechnology is Marianne De Backer, benoemd in Apr2023, heeft een ambtstermijn van 1.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 39.49M, bestaande uit 1.7% salaris en 98.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.052% van de aandelen van het bedrijf, ter waarde $ 532.70K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.7 jaar en 5.8 jaar.

Belangrijke informatie

Marianne De Backer

Algemeen directeur

US$39.5m

Totale compensatie

Percentage CEO-salaris	1.7%
Dienstverband CEO	1.6yrs
Eigendom CEO	0.05%
Management gemiddelde ambtstermijn	1.7yrs
Gemiddelde ambtstermijn bestuur	5.8yrs

Recente managementupdates

Recent updates

Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans?

Sep 08

Analysts Are Updating Their Vir Biotechnology, Inc. (NASDAQ:VIR) Estimates After Its Second-Quarter Results

Aug 03

Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis

Jul 17

Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Boosting Their Estimates

May 05

Vir Biotechnology, Inc. (NASDAQ:VIR) Analysts Just Slashed This Year's Revenue Estimates By 37%

Aug 07

Revenues Working Against Vir Biotechnology, Inc.'s (NASDAQ:VIR) Share Price Following 42% Dive

Jul 24

Analysts Just Shaved Their Vir Biotechnology, Inc. (NASDAQ:VIR) Forecasts Dramatically

Feb 28

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Could Be 26% Below Their Intrinsic Value Estimate

Jan 07

Vir Biotechnology: Focus On Hepatitis B Development Could End Up Paying Off

Oct 12

Vir Biotech gains 12% as U.S. govt. inks multi-year deal worth up to $1B

Oct 04

Analyse CEO-vergoeding

Hoe is Marianne De Backer's beloning veranderd ten opzichte van Vir Biotechnology's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$483m
Mar 31 2024	n/a	n/a	-US$539m
Dec 31 2023	US$39m	US$675k	-US$615m

Compensatie versus markt: De totale vergoeding ($USD 39.49M ) Marianne } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 3.21M ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Marianne te vergelijken met de prestaties van het bedrijf.

CEO

Marianne De Backer (55 yo)

1.6yrs

Tenure

US$39,491,495

Compensatie

Dr. Marianne De Backer, MSc, Ph. D. MBA, served as Independent Director at Kronos Bio, Inc. from January 25, 2021 to June 2023. Dr. De Backer served as Executive Vice President, Head of Global Business Dev...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Marianne De Backer	CEO & Director	1.6yrs	US$39.49m	0.052% $ 532.7k
Ann Hanly	Executive VP & Chief Technology Officer	3.7yrs	US$3.11m	0.029% $ 297.4k
Jeff Calcagno	Executive VP & Chief Business Officer	1.5yrs	US$4.54m	0.00023% $ 2.4k
Klaus Frueh	Co-Founder & Scientific Advisor	8.8yrs	US$177.66k	geen gegevens
Lawrence Corey	Co-Founder & Scientific Advisor	8.8yrs	geen gegevens	geen gegevens
Louis Picker	Co-Founder & Scientific Advisor	no data	geen gegevens	geen gegevens
Jason O'Byrne	Executive VP & CFO	less than a year	geen gegevens	geen gegevens
Brent Sabatini	Senior VP	1.8yrs	geen gegevens	0.021% $ 213.0k
Jennifer Towne	Executive VP & Chief Scientific Officer	less than a year	geen gegevens	geen gegevens
Heather Armstrong	Vice President of Investor Relations	no data	geen gegevens	geen gegevens
Vanina de Verneuil	Executive VP	2.2yrs	geen gegevens	0.048% $ 487.8k
Arran Attridge	Senior Vice President of Corporate Communications	less than a year	geen gegevens	geen gegevens

1.7yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van VIR wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.7 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Marianne De Backer	CEO & Director	1.6yrs	US$39.49m	0.052% $ 532.7k
Klaus Frueh	Co-Founder & Scientific Advisor	5.8yrs	US$177.66k	geen gegevens
Lawrence Corey	Co-Founder & Scientific Advisor	no data	geen gegevens	geen gegevens
Louis Picker	Co-Founder & Scientific Advisor	no data	geen gegevens	geen gegevens
Robert Taylor Nelsen	Independent Director	8.6yrs	US$454.90k	0.45% $ 4.6m
Robert J. More	Independent Director	8.2yrs	US$474.90k	0.028% $ 289.7k
Vicki Sato	Independent Chairman	7.9yrs	US$502.26k	0.97% $ 9.9m
George Scangos	Director	7.8yrs	US$688.20k	2.81% $ 28.7m
Thomas Daniel	Scientific Advisor	5.8yrs	US$23.92k	geen gegevens
Charles Rice	Scientific Advisor	no data	geen gegevens	geen gegevens
Jeffrey Hatfield	Independent Director	3.9yrs	US$472.17k	0.017% $ 178.3k
Sona Saira Ramasastry	Independent Director	5.2yrs	US$476.51k	0.011% $ 109.5k

5.8yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van VIR wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.8 jaar).

Vir Biotechnology Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Vir Biotechnology, Inc. Announces Executive Appointments

Vir Biotechnology, Inc. Appoints Mark D. Eisner as Executive Vice President and Chief Medical Officer, Effective June 3, 2024

Vir Biotechnology, Inc., Annual General Meeting, May 29, 2024

Vir Biotechnology, Inc., Annual General Meeting, May 29, 2024

CEO & Director recently sold US$690k worth of stock

Director notifies of intention to sell stock

Recent updates

Vir Biotechnology, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Vir Biotechnology, Inc. Announces Executive Appointments

Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans?

Consensus revenue estimates decrease by 18%, EPS upgraded

Analysts Are Updating Their Vir Biotechnology, Inc. (NASDAQ:VIR) Estimates After Its Second-Quarter Results

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Vir Biotechnology, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis

Vir Biotechnology, Inc.(NasdaqGS:VIR) dropped from Russell 2000 Value-Defensive Index

Vir Biotechnology, Inc. Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection

New minor risk - Share price stability

Vir Biotechnology, Inc. Announces New Preliminary Data from its Phase 2 SOLSTICE Hepatitis Delta Clinical Trial Evaluating tobevibart, an Investigational Monoclonalantibody, and Elebsiran

Vir Biotechnology, Inc. Appoints Mark D. Eisner as Executive Vice President and Chief Medical Officer, Effective June 3, 2024

Consensus revenue estimates increase by 78%

Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Boosting Their Estimates

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Vir Biotechnology Provides Some Hope For Its Beleaguered Shareholders

Vir Biotechnology, Inc., Annual General Meeting, May 29, 2024

Vir Biotechnology, Inc., Annual General Meeting, May 29, 2024

Vir Biotechnology, Inc. to Report Q1, 2024 Results on May 02, 2024

CEO & Director recently sold US$690k worth of stock

Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule

Director notifies of intention to sell stock

Vir Biotechnology: Making Progress In Hepatitis B And Hepatitis Delta

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Director notifies of intention to sell stock

Price target increased by 12% to US$29.50

Vir Biotechnology, Inc. Announces Phil Pang Will Step Down as Chief Medical Officer

Price target decreased by 32% to US$18.00

Vir Biotechnology, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Price target decreased by 10% to US$26.50

Sticking With Vir Biotechnology

Price target decreased by 9.2% to US$29.75

Price target decreased by 9.2% to US$29.75

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Vir Biotechnology, Inc. Appoints Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer

Vir Biotechnology, Inc. Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s the Liver Meeting® 2023

Vir Biotechnology, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Biomedical Advanced Research and Development Authority Awards Funding to Vir Biotechnology, Inc. to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats

Vir Biotechnology, Inc. Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV

New major risk - Revenue and earnings growth

Vir Biotechnology, Inc. (NASDAQ:VIR) Analysts Just Slashed This Year's Revenue Estimates By 37%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Vir Biotechnology, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Revenues Working Against Vir Biotechnology, Inc.'s (NASDAQ:VIR) Share Price Following 42% Dive

Consensus revenue estimates fall by 36%

Vir Biotechnology, Inc. Announces Topline Data from Phase 2 Peninsula Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness

Price target decreased by 24% to US$36.38

New minor risk - Share price stability

Independent Chairman notifies of intention to sell stock

Vir Biotechnology, Inc. Announces the Appointment of Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer, Effective July 10, 2023

Vir Biotechnology, Inc. Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D

Independent Director notifies of intention to sell stock

Vir Biotechnology, Inc. Elects Elliott Sigal as Director

Vir Biotechnology, Inc. Appoints Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer

Vir Biotechnology, Inc. Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNa and an NRTI

Consensus EPS estimates fall by 12%, revenue upgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Executive VP & Chief Technology Officer recently sold US$60k worth of stock

Independent Chairman notifies of intention to sell stock

Price target decreased by 7.5% to US$48.13

Analysts Just Shaved Their Vir Biotechnology, Inc. (NASDAQ:VIR) Forecasts Dramatically

Full year 2022 earnings released: EPS: US$3.89 (vs US$4.07 in FY 2021)

President notifies of intention to sell stock

Executive VP recently sold US$61k worth of stock

Vir Biotechnology, Inc. to Report Q4, 2022 Results on Feb 23, 2023

President notifies of intention to sell stock

Now 22% undervalued after recent price drop

Executive VP exercised options and sold US$836k worth of stock